Although not as notorious as its siblings such as hepatitis A and B, hepatitis C is a major cause of cirrhosis, liver failure, liver cancer and other serious diseases in humans. Hepatitis C is known as the “silent killer” due to its long incubation period and lack of obvious symptoms. In 2015, in order to prevent the spread of hepatitis C, the Ministry of Health of Laos established the “Hepatitis C Treatment Program” and selected “Sofosbuvir + Daclatasvir” as the treatment option. “In May of this year, Sofosbuvir+Daclatasvir was approved for marketing. The clinical evidence shows that these two drugs are almost identical to the EU combination, while their price is only about one-eighth of the latter. Currently, the Lao government has authorized its national infectious disease center, Friendship Hospital, to use the Sofinib + Dacortina regimen for the treatment of hepatitis C patients in the country and in neighboring countries such as China. The end of hepatitis C for the Chinese – “Sofinib + Dacortina” has arrived! The war against hepatitis C has never stopped, but for a long time the results have not been satisfactory. Not only did the cure rate of interferon combined with ribavirin hover around 50%, but there were also unbearable side effects – leukopenia, psychiatric abnormalities, kidney damage and autoimmune system diseases. It was only in 2014 that a new chapter in the treatment of hepatitis C DAAs (direct antivirals) was officially opened with the introduction of Gilead’s Sofosbuvir and Schweppes’ Daclatasvir. In a randomized clinical study of 211 cases published in 2014, EU physicians found that the combination of sofosbuvir and daclatasvir achieved a combined SVR12 of 95% for each genotype of hepatitis C, 99% for type 1, and 99.5% for SVR24, and that patients generally experienced fewer side effects during the drug administration. On May 28, 2015, the European Association for the Study of Liver Diseases recommended Sofosbuvir + Daclatasvir as the clinical formulation with the highest cure rate and the simplest dosing regimen for hepatitis C. This formulation was therefore called the “EU combination”. However, the most effective formulation is also the most expensive. Based on the pricing of both drugs in the US and EU, a 12-week course of treatment would cost no less than 1 million RMB. Due to patent protection, Chinese patients will not have access to relatively inexpensive generic drugs until at least 2024, and it is impossible to predict how many patients will die in that 10-year period because of lack of timely access to the drugs.